Repligen Corp (NASDAQ: RGEN)

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems to improve efficiency and flexibility in the manufacturing of biological drugs. The company serves biopharmaceutical companies contract development and manufacturing organizations and other life science firms that face pressure to increase production capacity lower costs and maintain quality. Its products support the production of monoclonal antibodies recombinant proteins RNA based therapeutics vaccines and cell and gene therapies.

Revenue is generated primarily from the sale of consumable and single use products as well as hardware and equipment across its four franchises. The company's offerings include filtration chromatography process analytics and protein based products that are used in upstream and downstream steps of biologics manufacturing. Customers purchase these products to enhance process control increase yields and reduce contamination risk.

The company operates through the following segments:

• Filtration includes Fluid Management and provides products such as XCell ATF cell retention systems Tangential Flow Filtration systems Flat Sheet Cassettes Hollow Fiber consumables and related fluid management components that support upstream and downstream biologics processing.

• Chromatography offers OPUS PrePacked Columns KRM Chromatography Systems and related consumables that enable downstream purification of biologics with reduced labor and consistent performance.

• Process Analytics provides slope spectroscopy based tools such as the PATsmart SoloVPE and FlowVPX systems and the recently acquired 908 Devices portfolio that enable real time concentration measurements and process control in biologics manufacturing.

• Proteins supplies affinity ligands and resins including Protein A ligands AVIPure resins for new modalities and growth factor proteins that are used to purify monoclonal antibodies and emerging biologics such as cell and gene therapies.

Repligen holds a leading position in the bioprocessing industry due to its broad product portfolio and focus on innovation. The company competes with major players such as Sartorius Danaher General Electric Healthcare and Cytiva but differentiates itself through its ability to offer integrated solutions that combine filtration chromatography analytics and protein products. Its strong intellectual property base and history of strategic acquisitions further support its competitive edge.

The company serves a diverse customer base that includes large multinational biopharmaceutical corporations contract development and manufacturing organizations and other life science firms engaged in the development and production of therapeutic proteins vaccines and advanced modalities.